跳至主要内容
临床试验/NCT01736163
NCT01736163已完成不适用

A Retrospective, Non-interventional Study of Patients With T4 Tumours Comparing the Thyroid Remnant Ablation Success Following Thyrogen and 131I Administration Versus Thyroid Hormone Withdrawal and 131I Administration

Genzyme, a Sanofi Company9 个研究点 分布在 4 个国家目标入组 144 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
144
试验地点
9
主要终点
First ablation success rate by Diagnostic Whole Body Scan (DxWBS)

研究概览

简要总结

The study is to demonstrate non-inferior thyroid remnant first ablation success of Thyrogen and 131I compared to thyroid hormone withdrawal (THW) and 131I in patients with T4 tumour based on historical diagnostic whole body scan (DxWBS) records.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Historical records from patients who meet all of the following criteria will be eligible for inclusion in this retrospective evaluation:
  • Male or female patients living or deceased, aged 18 years or older at the time of first ablation for thyroid cancer.
  • Diagnosed with a well-differentiated T4 tumour (defined as a primary tumour of any size that extends beyond the thyroid capsule [this may be referred to as TNM classification T4, N0-1, M0-1]). This excludes unusual histological types such as oncocytic (Hurthle cell carcinoma), tall cell, sclerosing or cribriform thyroid cancers.
  • Undergone a near-total or total thyroidectomy on or after 01 January 2000
  • Undergone first ablation of thyroid remnants with high activity 131I (≥28 mCi or ≥ 1.036 GBq).
  • Undergone first 131I ablation for the T4 tumour using either Thyrogen (0.9 mg IM on 2 consecutive days) or THW stimulation. This excludes use of non-standard Thyrogen regimens (i.e., had a regimen of Thyrogen other than the standard 0.9 mg IM on 2 consecutive days or received Thyrogen in combination with THW).
  • Historical records are available confirming ablation results by:
  • DxWBS using small activity (≥2 mCi or 74 MBq) of iodine 131I (or 123I) performed at least 6 months after administration of the first ablation activity of 131I and/or
  • Stimulated Tg measured at least 6 months after administration of the first ablation activity of 131I.

排除标准

  • Historical records from patients who meet any of the following criteria will be excluded from this retrospective evaluation:
  • Received propylthiouracil, methimazole, vitamins or supplements containing kelp or iodine (taking a multivitamin that does not contain iodine or kelp is acceptable), medications that significantly affect iodine handling such as high dose corticosteroids, high dose diuretics, or lithium in the 45 days before administration of first ablative activity of 131I.
  • Received any iodine-containing contrast agents within 3 months prior to first ablative activity of 131I administered.
  • Used amiodarone within the 2 years prior to first ablative activity of 131I administered.

研究组 & 干预措施

Thyrogen and 131I

Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.

干预措施: Thyrogen (Drug)

Thyrogen and 131I

Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.

干预措施: 131I (Drug)

Thyroid Hormone Withdrawal and 131I

Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.

干预措施: 131I (Drug)

Thyroid Hormone Withdrawal and 131I

Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.

干预措施: Thyroid Hormone Withdrawal (Other)

结局指标

主要结局

First ablation success rate by Diagnostic Whole Body Scan (DxWBS)

时间窗: at least 6 months after administration of first ablation activity of 131I

次要结局

  • First ablation success rate based on stimulated Thyroglobulin (Tg) levels(at least 6 months after administration of first ablation activity of 131I)
  • First ablation success rate based on historical records(at least 6 months after administration of first ablation activity of 131I)
  • Number of adverse events of Thyrogen and 131I arm and THW and 131I arm(Within 30 days of treatment.)

研究者

发起方
Genzyme, a Sanofi Company
申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验